Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 58, Issue 7, 2008, Pages 2098-2104

  Graham, Kareem L ^a   Lee, Lowen Y ^a   Higgins, John P ^a   Steinman, Lawrence ^a   Utz, Paul J ^a   Ho, Peggy P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; DOUBLE STRANDED DNA ANTIBODY; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; KIDNEY DISEASE; LYMPHOCYTE PROLIFERATION; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, ANTINUCLEAR; CELL PROLIFERATION; CHOLESTEROL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-4; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; PYRROLES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 47249120828     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23605     Document Type: Article

References (15)

1. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus [review]. Lupus 2004;13:366-71.
2. Byrd J, Waselenko J, Maneatis T, Murphy T, Ward F, Monahan B, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791-5.
3. Oellerich M, Shipkova M, Schutz E, Wieland E, Weber L, Tonshoff B, et al, for the German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring [review]. Ther Drug Monit 2000;22:20-6.
4. Bruce I. Atherogenesis and autoimmune disease: the model of lupus [review]. Lupus 2005;14:687-90.
5. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-95.
6. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
7. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin [review]. Cardiovasc Drugs Ther 2001;15:211-8.
8. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006;203:401-12.
9. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004;173:7641-6.
10. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-8.
11. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70.
12. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607-11.
13. Palomer X, Calpe-Berdiel L, Verdaguer J, Carrillo J, Pastor X, Mauricio D, et al. Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes. Diabetologia 2005;48:1671-3.
14. Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006;177:3028-34.
15. Pierno S, Didonna M, Cippone V, De Luca A, Pisoni M, Frigeri A, et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol 2006;149:909-19.